Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

ASCENTAGE PHARMA GROUP INTERNATIONAL
亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

DIS-APPLICATION OF RULES 18A.09 TO 18A.11 OF THE LISTING RULES AND REMOVAL OF STOCK MARKER

Ascentage Pharma Group International (the "**Company**") is pleased to announce that following an application to The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the Stock Exchange has granted approval for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules (the "**Relevant Rules**") to the Company.

As a result of the dis-application of the Relevant Rules, the "B" marker will no longer be affixed to the Company's English and Chinese short name from June 1, 2026. The Company's shares will be traded on the Stock Exchange under the new stock short name of "ASCENTAGE" in English and "亞盛醫藥" in Chinese. The stock code of the Company remains unchanged as "6855".

REASONS FOR THE DIS-APPLICATION OF THE RELEVANT RULES

The Company is a biotechnology company whose ordinary shares (the "**Shares**") were listed on the Main Board of the Stock Exchange on October 28, 2019, and subject to the application of, among others, Rules 18A.09 to 18A.11 of the Listing Rules.

The Company now satisfies the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules. In particular, the Company has (i) a trading record of at least three financial years; (ii) management continuity for at least the three preceding financial years (i.e. the years ended December 31, 2023, 2024 and 2025) and up to the date of this announcement; and (iii) ownership continuity and control for at least the most recent audited financial year (i.e. the year ended December 31, 2025) and up to the date of this announcement. The Company's market capitalization as of May 27, 2026 was approximately HKD14.96 billion, which significantly exceeds the HKD4.0 billion as required under Rule 8.05(3) of the Listing Rules. As stated in the annual results announcement of the Company for the year ended 31 December 2025, the Company's revenue for the year ended 31 December 2025, being the most recent audited financial year, generated from its core products, Olverembatinib and Lisaftoclax, was in excess of HKD500.0 million as required under Rule 8.05(3) of the Listing Rules. Accordingly, the Company qualifies for listing under Rule 8.05(3) of the Listing Rules and the Stock Exchange has therefore granted its approval for the application for dis-application of the Relevant Rules to the Company.

EFFECTS OF THE DIS-APPLICATION OF THE RELEVANT RULES

Following the dis-application of the Relevant Rules, the "B" marker will cease to be affixed to the Company's English and Chinese stock short name. There will be otherwise no effect on the existing share certificates in respect of the Company's Shares which will continue to be good evidence of legal title and be valid for trading, settlement and registration purposes and will not involve any transfer or exchange of the existing share certificates for holders of the Company's Shares. No other changes will be made to the English or Chinese stock short name of the Company, the existing share certificates, the board lot size, the trading currency of the Company's Shares and the share registrar and transfer offices of the Company following the dis-application of the Relevant Rules.

By Order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, the People's Republic of China, May 27, 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong[Note 1] as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky[Note 2], Ms. Marina S. Bozilenko, Dr. Debra Yu and Marc E. Lippman, MD as independent non-executive Directors.

Notes:

1. *Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements.*

2. *Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.*